• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

当应用严格的计数指南时,肺神经内分泌肿瘤的Ki-67标记指数在活检样本和手术标本之间具有高度的一致性。

Ki-67 labeling index of neuroendocrine tumors of the lung has a high level of correspondence between biopsy samples and surgical specimens when strict counting guidelines are applied.

作者信息

Fabbri Alessandra, Cossa Mara, Sonzogni Angelica, Papotti Mauro, Righi Luisella, Gatti Gaia, Maisonneuve Patrick, Valeri Barbara, Pastorino Ugo, Pelosi Giuseppe

机构信息

Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.

Department of Oncology, University of Turin, Turin, Italy.

出版信息

Virchows Arch. 2017 Feb;470(2):153-164. doi: 10.1007/s00428-016-2062-2. Epub 2017 Jan 4.

DOI:10.1007/s00428-016-2062-2
PMID:28054150
Abstract

Optimal histopathological analysis of biopsies from metastases of neuroendocrine tumor (NET) of the lung requires more than morphology only. Additional parameters such as Ki-67 labeling index are required for adequate diagnosis, but few studies have compared reproducibility of different counting protocols and modalities of reporting on biopsies of lung NET. We compared the results of four different manual counting techniques to establish Ki-67 LI. On 47 paired biopsies and surgical specimens from 22 typical carcinoids (TCs), 14 atypical carcinoids (ACs), six large cell neuroendocrine carcinomas (LCNECs), and five small cell carcinomas (SCCs) immunohistochemical staining of Ki-67 antigen was performed. We counted, in regions of highest nuclear staining (HSR), a full ×40-high-power field (diameter = 0.55 mm), 500 or 2000 cells, or 2 mm surface area, including the HSR or the entire biopsy fragment(s). Mitoses and necrosis were evaluated in an area of 2 mm or the entire biopsy fragment(s). Between the four counting methods, no differences in Ki-67 LI were observed. However, a Ki-67 LI higher than 5% was found in only four cases when in an HSR, 500 cells were counted (18%), five (23%) when in an HSR 2000 cells were counted, four (18%) when 2 mm were counted, and one (5%) TC case when the entire biopsy was counted. A 20% cutoff distinguished TC and AC from LCNEC and SCC with 100% specificity and sensitivity, while mitoses and necrosis failed to a large extent. Ki-67 LI in biopsy samples was concordant with that in resection specimens when 2000 cells, 2 mm, or the entire biopsy fragment(s) were counted. Our results are important for clinical management of patients with metastases of a lung NET.

摘要

对肺神经内分泌肿瘤(NET)转移灶活检进行最佳组织病理学分析,所需的不仅仅是形态学检查。为了进行充分诊断,还需要诸如Ki-67标记指数等其他参数,但很少有研究比较不同计数方案和肺NET活检报告方式的可重复性。我们比较了四种不同的手动计数技术来确定Ki-67 LI。对来自22例典型类癌(TC)、14例非典型类癌(AC)、6例大细胞神经内分泌癌(LCNEC)和5例小细胞癌(SCC)的47对活检标本和手术标本进行了Ki-67抗原的免疫组化染色。我们在核染色最高区域(HSR)计数一个完整的×40高倍视野(直径 = 0.55 mm)、500或2000个细胞,或2 mm表面积,包括HSR或整个活检片段。在2 mm区域或整个活检片段中评估有丝分裂和坏死情况。在这四种计数方法之间未观察到Ki-67 LI的差异。然而,当在HSR中计数500个细胞时,仅4例(18%)发现Ki-67 LI高于5%;计数2000个细胞时为5例(23%);计数2 mm时为4例(18%);对整个活检进行计数时,1例(仅1例TC)(5%)。以20%为临界值区分TC和AC与LCNEC和SCC,特异性和敏感性均为100%,而有丝分裂和坏死在很大程度上无法区分。当计数2000个细胞、2 mm或整个活检片段时,活检样本中的Ki-67 LI与切除标本中的Ki-67 LI一致。我们的结果对肺NET转移患者的临床管理具有重要意义。

相似文献

1
Ki-67 labeling index of neuroendocrine tumors of the lung has a high level of correspondence between biopsy samples and surgical specimens when strict counting guidelines are applied.当应用严格的计数指南时,肺神经内分泌肿瘤的Ki-67标记指数在活检样本和手术标本之间具有高度的一致性。
Virchows Arch. 2017 Feb;470(2):153-164. doi: 10.1007/s00428-016-2062-2. Epub 2017 Jan 4.
2
Automated quantification of Ki-67 index associates with pathologic grade of pulmonary neuroendocrine tumors.自动量化 Ki-67 指数与肺神经内分泌肿瘤的病理分级相关。
Chin Med J (Engl). 2019 Mar 5;132(5):551-561. doi: 10.1097/CM9.0000000000000109.
3
What clinicians are asking pathologists when dealing with lung neuroendocrine neoplasms?临床医生在处理肺神经内分泌肿瘤时会向病理学家询问哪些问题?
Semin Diagn Pathol. 2015 Nov;32(6):469-79. doi: 10.1053/j.semdp.2015.10.009. Epub 2015 Oct 22.
4
Orthopedia homeobox is preferentially expressed in typical carcinoids of the lung.骨形成蛋白同源盒基因在肺典型类癌中优先表达。
Cancer Cytopathol. 2018 Apr;126(4):236-242. doi: 10.1002/cncy.21969. Epub 2018 Jan 9.
5
ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival.ERCC1 和 Ki67 在小细胞肺癌和其他肺神经内分泌肿瘤中的表达:分布与生存的关系。
J Thorac Oncol. 2010 Apr;5(4):453-9. doi: 10.1097/JTO.0b013e3181ca063b.
6
Immunohistochemical analysis of OTP and NKX6.1 in neuroendocrine tumors of the lung and pancreas.肺和胰腺神经内分泌肿瘤中OTP和NKX6.1的免疫组织化学分析
Diagn Cytopathol. 2018 Dec;46(12):1010-1014. doi: 10.1002/dc.24088. Epub 2018 Oct 3.
7
Automated quantification of Ki-67 proliferative index of excised neuroendocrine tumors of the lung.肺切除神经内分泌肿瘤Ki-67增殖指数的自动化定量分析
Diagn Pathol. 2014 Oct 16;9:174. doi: 10.1186/s13000-014-0174-z.
8
Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.肺神经内分泌肿瘤中p53、K-ras-2和C-raf-1的分析。与组织学亚型和临床结果的相关性。
Am J Pathol. 1996 May;148(5):1531-41.
9
Comparative evaluation of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in bronchopulmonary neuroendocrine neoplasms: Issues and prospects.支气管肺神经内分泌肿瘤中三种增殖标志物Ki-67、TOP2A和RacGAP1的比较评估:问题与前景
Oncotarget. 2016 Jul 5;7(27):41959-41973. doi: 10.18632/oncotarget.9747.
10
Can the Ki-67 Labeling Index in Biopsy Specimens Predict the World Health Organization Grade of Rectal Neuroendocrine Tumors?活检标本中的Ki-67标记指数能否预测世界卫生组织直肠神经内分泌肿瘤分级?
Dig Dis. 2018;36(2):118-122. doi: 10.1159/000484083. Epub 2017 Oct 31.

引用本文的文献

1
Clinical needs and pathology's answers in neuroendocrine neoplasms of the lung.肺部神经内分泌肿瘤的临床需求与病理学解答
Pathologica. 2025 Jun;117(3):220-242. doi: 10.32074/1591-951X-N1102. Epub 2025 Jun 27.
2
Assessment of the current and emerging criteria for the histopathological classification of lung neuroendocrine tumours in the lungNENomics project.评估肺神经内分泌肿瘤组织病理学分类的现行和新兴标准——肺神经内分泌肿瘤组学项目。
ESMO Open. 2024 Jun;9(6):103591. doi: 10.1016/j.esmoop.2024.103591. Epub 2024 Jun 14.
3
Comparison Between Manual and Automated Assessment of Ki-67 in Breast Carcinoma: Test of a Simple Method in Daily Practice.

本文引用的文献

1
Grading lung neuroendocrine tumors: Controversies in search of a solution.肺神经内分泌肿瘤的分级:寻求解决方案中的争议
Histol Histopathol. 2017 Mar;32(3):223-241. doi: 10.14670/HH-11-822. Epub 2016 Sep 15.
2
Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.肺大细胞神经内分泌癌的下一代测序揭示了小细胞癌样和非小细胞癌样亚组。
Clin Cancer Res. 2016 Jul 15;22(14):3618-29. doi: 10.1158/1078-0432.CCR-15-2946. Epub 2016 Mar 9.
3
Diagnosis and management of typical and atypical lung carcinoids.
Ki-67 在乳腺癌中手动和自动评估的比较:日常实践中简单方法的检验。
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231169603. doi: 10.1177/15330338231169603.
4
Proposing Specific Neuronal Epithelial-to-Mesenchymal Transition Genes as an Ancillary Tool for Differential Diagnosis among Pulmonary Neuroendocrine Neoplasms.提出特定的神经元上皮-间充质转化基因作为肺神经内分泌肿瘤鉴别诊断的辅助工具。
Genes (Basel). 2022 Dec 7;13(12):2309. doi: 10.3390/genes13122309.
5
Utility of KI-67 as a prognostic biomarker in pulmonary neuroendocrine neoplasms: a systematic review and meta-analysis.KI-67 在肺神经内分泌肿瘤中的预后生物标志物效用:系统评价和荟萃分析。
BMJ Open. 2022 Mar 3;12(3):e041961. doi: 10.1136/bmjopen-2020-041961.
6
Liquid Biopsy as a Prognostic and Theranostic Tool for the Management of Pancreatic Ductal Adenocarcinoma.液体活检作为胰腺导管腺癌管理的预后和治疗诊断工具
Front Med (Lausanne). 2022 Jan 14;8:788869. doi: 10.3389/fmed.2021.788869. eCollection 2021.
7
Lung neuroendocrine tumors: A systematic literature review (Review).肺神经内分泌肿瘤:一项系统文献综述(综述)
Exp Ther Med. 2022 Feb;23(2):176. doi: 10.3892/etm.2021.11099. Epub 2021 Dec 28.
8
The Ki-67 antigen in the new 2021 World Health Organization classification of lung neuroendocrine neoplasms.新版 2021 年世界卫生组织肺神经内分泌肿瘤分类中的 Ki-67 抗原。
Pathologica. 2021 Oct;113(5):377-387. doi: 10.32074/1591-951X-542.
9
Intratumor Distribution of Ki-67 Antigen Beyond Labeling Index for Clinical Decision-Making: A New Way of Counting.超越标记指数的Ki-67抗原在肿瘤内的分布用于临床决策:一种新的计数方法
JTO Clin Res Rep. 2021 Sep 24;2(9):100207. doi: 10.1016/j.jtocrr.2021.100207. eCollection 2021 Sep.
10
Lung neuroendocrine neoplasms: recent progress and persistent challenges.肺神经内分泌肿瘤:最新进展与持续挑战。
Mod Pathol. 2022 Jan;35(Suppl 1):36-50. doi: 10.1038/s41379-021-00943-2. Epub 2021 Oct 18.
典型和非典型肺类癌的诊断和治疗。
Crit Rev Oncol Hematol. 2016 Apr;100:167-76. doi: 10.1016/j.critrevonc.2016.02.009. Epub 2016 Feb 18.
4
Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes.肺大细胞神经内分泌癌:临床病理特征、治疗及预后
Clin Lung Cancer. 2016 Sep;17(5):e121-e129. doi: 10.1016/j.cllc.2016.01.003. Epub 2016 Jan 21.
5
Neuroendocrine Cancer of the Lung: A Diagnostic Puzzle.肺神经内分泌癌:诊断难题。
J Thorac Oncol. 2016 Mar;11(3):e35-8. doi: 10.1016/j.jtho.2015.10.013. Epub 2015 Dec 24.
6
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.依维莫司治疗晚期肺或胃肠道无功能性神经内分泌肿瘤(RADIANT-4):一项随机、安慰剂对照的3期研究。
Lancet. 2016 Mar 5;387(10022):968-977. doi: 10.1016/S0140-6736(15)00817-X. Epub 2015 Dec 17.
7
Genomic architecture of lung cancers.肺癌的基因组结构
Curr Opin Oncol. 2016 Jan;28(1):52-7. doi: 10.1097/CCO.0000000000000251.
8
What clinicians are asking pathologists when dealing with lung neuroendocrine neoplasms?临床医生在处理肺神经内分泌肿瘤时会向病理学家询问哪些问题?
Semin Diagn Pathol. 2015 Nov;32(6):469-79. doi: 10.1053/j.semdp.2015.10.009. Epub 2015 Oct 22.
9
Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.具有形态学上明显高级别成分的高分化神经内分泌肿瘤:一条与低分化神经内分泌癌不同的途径。
Clin Cancer Res. 2016 Feb 15;22(4):1011-7. doi: 10.1158/1078-0432.CCR-15-0548. Epub 2015 Oct 19.
10
Medical Therapy of Pulmonary Neuroendocrine Neoplasms: Targeted, Symptomatic and Chemotherapy.肺神经内分泌肿瘤的医学治疗:靶向治疗、对症治疗和化疗
Front Horm Res. 2015;44:193-7. doi: 10.1159/000402752. Epub 2015 Aug 14.